To date, there are four pharmacological options approved for the symptomatic treatment of AD: Memantine, which is a N-methyl-d-aspartate (NMDA) receptor antagonist, and three acetylcholinesterase (AChE) inhibitors, namely Rivastigmine, Donepezil (DPZ), and Galantamine [5]. Here, ACHE is linked to Alzheimer disease.